Suzano (SUZB3) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
18 Nov, 2025Executive summary
Q1 2025 results aligned with management's plan, with inventory rebuilt to normalized levels despite concentrated maintenance downtimes and operational readiness remaining strong.
Focus remains on strengthening competitive position and deleveraging amid escalating global uncertainty and cost competitiveness, with US packaging operations nearing breakeven.
Free cash flow generation is resilient across pulp price scenarios, with ongoing efforts to reduce cash and SG&A costs.
Consolidated adjusted EBITDA was R$4.9 billion, down 25% from 4Q24 and up 7% year-over-year; operating cash generation reached R$2.6 billion, down 46% sequentially but up 5% year-over-year.
Net income was R$6.3 billion, a significant turnaround from a R$6.7 billion loss in 4Q24 and up from R$220 million in 1Q24, mainly due to positive financial results from BRL appreciation.
Financial highlights
Net revenue was R$11.6 billion, down 19% from 4Q24 but up 22% year-over-year, with 81% from exports.
Adjusted EBITDA margin was 42%, down from 46% in 4Q24 and 48% in 1Q24.
Net debt stood at US$12.9 billion (R$74.2 billion), with leverage at 3.0x in USD and 3.1x in BRL.
Free cash flow yield (LTM) reached 18.5%, up 3.2 p.p. year-over-year.
Gross margin was 33%, down from 40% in 1Q24.
Outlook and guidance
Cash production costs expected to decline in coming quarters, with Q4 2024 as a reference for 2025.
Free cash flow generation anticipated under any pulp scenario; US packaging operations expected to reach breakeven soon.
Total operational expenditure for 2027 is forecast at R$1,900/t, progressing as planned.
Cerrado project capex is 97% complete, with R$0.6 billion remaining for 2025.
Latest events from Suzano
- Record sales, cost discipline, and strong liquidity support a positive outlook.SUZB3
Q4 202511 Feb 2026 - EBITDA up 60% year-over-year, but net loss of R$3.77B on FX and derivative impacts.SUZB3
Q2 20241 Feb 2026 - EBITDA and sales volumes surged, with Ribas ramp-up and acquisitions boosting performance.SUZB3
Q3 202418 Jan 2026 - Cost leadership, operational excellence, and disciplined capital allocation drive growth.SUZB3
Investor Day 202411 Jan 2026 - Record sales and EBITDA driven by Ribas ramp-up, but FX losses led to a net loss.SUZB3
Q4 20248 Jan 2026 - Focus is on competitiveness, cost reduction, and disciplined growth amid market shifts.SUZB3
Investor Day 202512 Dec 2025 - Strong sales growth, robust cash flow, and major strategic moves marked the quarter.SUZB3
Q2 202523 Nov 2025 - JV creates a global tissue leader with $3.3bn revenue, $175M synergies, and strong diversification.SUZB3
Investor Update12 Nov 2025 - Cash cost below BRL 800/ton, EBITDA down 20%, leverage up, 2025 capex guidance reaffirmed.SUZB3
Q3 20257 Nov 2025